Carlos Cruchaga

Professor of Psychiatry

Additional Titles & Roles


  • Knight-ADRC Genetics and Hight-throughput Omics Core leader
  • DIAN (The Dominantly Inherited Alzheimer Network) Genetics Core co-leader
  • Scientific advisor McDonnell Genome Institute (MGI)
  • Director NeuroGenomics and Informatics lab

Education & Training


  • PhD: Molecular and Cell Biology: University of Navarra, Pamplona, Spain, 2005
  • BA: Biochemistry and Molecular Biology: University of Navarra, Pamplona, Spain, 2002

Research Interests


Genetic and multi-omic approaches to identify novel variants, genes and pathways implicated on neurodegeneration, with the ultimate goal of understanding the biology of neurodegenerative diseases

Visit lab website

Key Publications


See more publications

Funded Research Projects


NIH-funded projects:
NIA (PI):Identification and Characterization of AD Risk Pathways using Multi-dimensional “OMICS” Data

NIA (PI):The Familial Alzheimer Sequencing (FASe) Project

NIA (PI): Identifying Rare Variants that Increase Risk for Alzheimer’s Disease

NIA (PI): Using Quantitative Traits to Identify Novel Genes for Alzheimer’s Disease and Other Complex Traits

NIA (PI): Phenotypic and Genetic Analysis of Soluble TREM2 in Cerebrospinal Fluid in AD

NIA (Site-PI):The National Institute on Aging (NIA) Late Onset of Alzheimer’s Disease (LOAD) Family Based Study (FBS)

NIA (Core Leader): Alzheimer’s Disease Research Center

NIA (Core Leader): Dominantly Inherited Alzheimer Network

NIA (Core Leader):DIAN-TU: Next Generation Prevention Trial

Non-profit
Alzheimer’s Association (PI): Functional Chracterization of Coding Risk Variants in TREM2 and PLD3

McDonnell Center for Cellular and Molecular Neurobiology (Co-PI):Characterization of the Brain Cellular Population Structure Altered in Alzheimer’s Disease

NIA (Investigator): Defining the Mechanisms by Which MS4A Genes Regulate TREM2 in Alzheimer Disease

Chan Zuckerberg Initiative/CZI (Co-PI): Molecular Mechanisms of the Central Regulator of TREM2 Dysfunction

Michael J. Fox Foundation for Parkinson’s Research (PI) :Leveraging Multi-Omics Data to Identify Common Pathways and Biomarkers for AD and PD

Industry:
Alector LLC (PI): Mendelian Randomization for Unbiased Biomarker Discovery for AD

Biogen (PI): Identifying Genetic Variants Associated with Stroke Outcomes